New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma

By Burton Jack D   Goldenberg David M  

Expert Opinion on Emerging Drugs, Vol. 15, Iss. 4, 2010-12 ,pp. : 569-583

Informa Healthcare

Access to resources Recommend Favorite

Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma

By Civallero Monica   Cosenza Maria   Bari Alessia   Sacchi Stefano  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 8, 2011-08 ,pp. : 1029-1031

Informa Healthcare

Access to resources Recommend Favorite

Risk factors for developing infusion reaction after rituximab administration in patients with B-cell non-Hodgkin's lymphoma

By Tachi T.   Yasuda M.   Usui K.   Umeda M.   Nagaya K.   Osawa T.   Ichihashi A.   Noguchi Y.   Goto H.   Kasahara S.   Takahashi T.   Goto C.   Teramachi H.  

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 70, Iss. 10, 2015-10 ,pp. : 674-677

Govi-Verlag

Access to resources Recommend Favorite

Emerging drugs for Hodgkin's lymphoma

By Böll Boris   Borchmann Peter   Diehl Volker  

Expert Opinion on Emerging Drugs, Vol. 15, Iss. 4, 2010-12 ,pp. : 585-595

Informa Healthcare

Access to resources Recommend Favorite

A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

By  

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3465-3471

Blackwell Publishing

Access to resources Recommend Favorite